Insider trade

Officer sold ~$616K of MRK shares in the open market

Traded Nov 10, 2025 · Filed Nov 12, 2025

MerckMRK

~$616K
Reported value · 7,085 sh @ $87.00: +65.8%
stock since the trade · S&P 500 +12.1%, $86.75 → $143.81 on Oct 1

Why it stands out

Merck's Chief Comm. & Public Afrs Ofcr sold $616K of Merck shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 10, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 12, 2025

Officer$500K–$1M

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$616,395

Shares × reported transaction price

Timing vs results

11 days after results of Oct 30, 2025, 85 days before results of Feb 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $86.75 on Nov 10, 2025, 18% above its 52-week low and 16% below its high, after a 10% rise over the previous 30 trading days

52-week range $73.47 (May 14, 2025) to $103.79 (Dec 9, 2024), 44% of the way up, from 250 adjusted closes. 30 trading days earlier: $78.58 on Sep 29, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Feb 12, 2025 in the U.S. District Court, D. New Jersey. A filing is an allegation, not a finding.

IN RE MERCK & CO., INC. SECURITIES LITIGATION, docket 2:25-cv-01208, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Keytruda on Nov 21, 2025, 11 days after this trade.

New use approved (efficacy supplement). Active ingredient: Pembrolizumab. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+2.2%	-2.9%	+5.1%
30 days	+7.9%	+1.3%	+6.6%
90 days	+28.4%	+3.0%	+25.4%
180 days	+20.9%	+9.8%	+11.1%

Past results only. Not a forecast.

Source receipt

Record ID: 0000310158-25-000061
Filed / recorded: Nov 12, 2025, 9:01 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Merck & Co., Inc.
Issuer CIK: 310158
Ticker: MRK
Reporting person: Cristal N Downing
Relationship: Officer
Officer title: Chief Comm. & Public Afrs Ofcr
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 10, 2025
Transaction code: S
Shares / units: 7,085
Price per share: $87.00
Acquired / disposed: Disposed (D)
Shares owned after: 0
Ownership form: Direct
Amendment: No

Around the same time

10mo ago

Congress trade

$1,001 - $15,000Reported range · official band, not an exact amount

5 different filers disclosed MRK within 90 days. Disclosed 28 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

Officer sold ~$720K of Merck

Automatic sale11mo ago

12mo ago

Congress trade

$1,001 - $15,000Reported range · official band, not an exact amount

6 different filers disclosed MRK within 90 days. Disclosed 17 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record